Jaime Caro
机构: Prof Medicine, Epidemiology & Biostatistics
每年引用次数
引用次数
引用: 24,462
H-指数: 71
I10-指数 : 199
出版物: 623
PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS
D. Zou , N. Desrosiers , S. Wu , T. Prawitz
Value in Health 21
2018
PUK6 Economic Modelling of Chronic Kidney Disease (CKD) Using Estimated Glomerular Filtration RATE (EGFR)- Slope: Effect on CKD Modelling of Acceptance of a New Surrogate Outcome
K. Marczell , P. Gal , Á. Benedict , J.M. Stavas
Value in Health 23
2020
Shortcutting Drug Development: Economic Benefits Of Using Genome-Wide Association Studies (Gwas) To Reposition Existing Drugs To Other Therapeutic Areas
J.J. Caro , B. Richards
Value in Health 17 ( 3) A26
2014
Estimating the life years gained from preventing cardiovascular disease
J.J. Caro , W.S. Klittich
Journal of the American College of Cardiology 31 ( 2) 48
1
1998
Evidence based medicine needs more evidence
J.J. Caro
Journal of the American College of Cardiology 31 48 -49
1998
PRM21 Communicating to Decision Makers the Parameter Uncertainty in the IQWiG Efficiency Frontier Approach
B. Stollenwerk , A. Briggs , E. Fenwick , J.J. Caro
Value in Health 15 ( 7) A463
2012
PRO69 EPIDEMIOLOGICAL MODEL TO SUPPORT ORPHAN DESIGNATION DECISIONS: A DICE SIMULATION STUDY
L. Mohseninejad , C. Pelligra , J.J. Caro
Value in Health 22
2019
Behavioral disturbances in dementia: An identifiable cost factor in long term care institutionalization
J.A. O’Brien , L.A. Shomphe , J.J. Caro
Biological Psychiatry 42 ( 1) 85
1997
Medical and social service resources available to dementia patients and their caregivers: An international survey
K.A. Payne , C. Wilson , J.J. Caro , J.A. O’Brien
Biological Psychiatry 42 ( 1) 84
1997
Behavioral disturbances in dementia as a factor in institutionalization
K.A. Payne , J.J. Caro
Biological Psychiatry 42 ( 1) 210
4
1997
PRM48 DESIGN AND OPERATIONAL CONSIDERATIONS FOR PRAGMATIC CLINICAL TRIALS TO SUPPORT HEOR EVALUATIONS
K.J. Ishak , K.A. Payne , M. Schrammel , J.J. Caro
Value in Health 14 ( 3) A154
1
2011
PRS45 MODELING THE IMPACT OF MULTIPLE QUIT ATTEMPTS IN SMOKERS USING DISCRETE EVENT SIMULATION (DES)
J. Marton , D. Getsios , N. Revankar , R.J. Willke
Value in Health 14 ( 3) A145
2011
Involvement of multiple vascular beds, CVD risk, and the benefits of prevention
J.J. Caro , K. Migliaccio-Walle , I. Thizon-de Gaulle , A.A. Coniglio
Atherosclerosis 144 17
1
1999
Cost-effectiveness of statins for primary and secondary prevention: A continuum of risk model linking WOSCOPS and care
J.J. Caro , W. Klittich , A. McGuire , G. L'Italien
Atherosclerosis 144 25
1999
C5. Beyond acute care: the true cost of stroke
J.A. O'Brien , J.J. Caro , W.S. Klittich
Clinical Therapeutics 18 21
5
1996
P25. PRISM: delivering the pharmacoeconomic message
J.J. Caro , J.A. O'Brien , W.S. Klittich
Clinical Therapeutics 18 60
1996
Long term cost-of-illness in stroke: an international review.
Krista A. Payne , Krista F. Huybrechts , Jjaime Caro , Traci J. Craig Green
PharmacoEconomics 20 ( 12) 813 -825
79
2002
Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.
J. Jaime CARO , Krista F. HUYBRECHTS , Guy DE BACKER , Dirk DE BACQUER
Acta Cardiologica 55 ( 4) 239 -246
14
2000
Atrial fibrillation and anticoagulation: from randomised trials to practice
J.J Caro , K.M Flegel , P.A Groome
The Lancet 341 ( 8857) 1381 -1384
36
1993
Instituting a routine varicella vaccination program in Canada: an economic evaluation.
DENIS GETSIOS , J. JAIME CARO , GRACIELA CARO , PHILLIPE DE WALS
Pediatric Infectious Disease Journal 21 ( 6) 542 -547
31
2002